Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
CAR-T Meeting 2023
Which podcast episodes came out on top this year? Time to find out! 😁
🎧 Here's our Top 6:
1) iwMPN 2025 highlights: novel approaches to the upfront management of #myelofibrosis, cardiovascular health in MPNs, & more
2) Diagnosing #amyloidosis: identifying early signs,
Which of our podcast episodes were the most popular in 2025?🤔🎧
🎙️Time to break down the Top 10, starting with 7th-10th place:
7) Post-ASH #myeloma highlights: key takeaways for community physicians & trials to look out for in 2025
8) Approaches to optimizing induction
Listen to our podcast on the top updates in MDS from ASH 2025🩸
👉https://ow.ly/AauY50XJuV1👈
Featuring experts @Dr_AmerZeidan (@YaleMed), @Santin13Valeria, Jacqueline Garcia (@DanaFarber), and Daniel Wiseman (@OfficialUoM).
#ASH25 #MDSsm, @ASH_hematology #HemOnc
It was a pleasure to speak with Gail Roboz of @WeillCornell at #ASH25 to hear about her AML highlights from this year's meeting. 😊🩸
Click here to watch the interview:
👉 👈
#AMLsm #Leusm #Leukemia #HemOnc @ASH_hematology
AML highlights from ASH 2025: menin inhibitor combinations, MRD, and real-world data
Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, shares her highlights in acute myeloid leukemia (AML) f...
ow.ly
🚨Earlier use of cilta-cel in #myeloma in the CARTITUDE-4 trial is associated with better immune fitness & stronger immune effects!
Samir Parekh of @IcahnMountSinai presented this hot abstract at #ASH25, and you can hear all about it in this interview:
🎥
CAR-T Meeting 2023
Which podcast episodes came out on top this year? Time to find out! 😁
🎧 Here's our Top 6:
1) iwMPN 2025 highlights: novel approaches to the upfront management of #myelofibrosis, cardiovascular health in MPNs, & more
2) Diagnosing #amyloidosis: identifying early signs,
Which of our podcast episodes were the most popular in 2025?🤔🎧
🎙️Time to break down the Top 10, starting with 7th-10th place:
7) Post-ASH #myeloma highlights: key takeaways for community physicians & trials to look out for in 2025
8) Approaches to optimizing induction
Listen to our podcast on the top updates in MDS from ASH 2025🩸
👉https://ow.ly/AauY50XJuV1👈
Featuring experts @Dr_AmerZeidan (@YaleMed), @Santin13Valeria, Jacqueline Garcia (@DanaFarber), and Daniel Wiseman (@OfficialUoM).
#ASH25 #MDSsm, @ASH_hematology #HemOnc
It was a pleasure to speak with Gail Roboz of @WeillCornell at #ASH25 to hear about her AML highlights from this year's meeting. 😊🩸
Click here to watch the interview:
👉 👈
#AMLsm #Leusm #Leukemia #HemOnc @ASH_hematology
AML highlights from ASH 2025: menin inhibitor combinations, MRD, and real-world data
Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, shares her highlights in acute myeloid leukemia (AML) f...
ow.ly
🚨Earlier use of cilta-cel in #myeloma in the CARTITUDE-4 trial is associated with better immune fitness & stronger immune effects!
Samir Parekh of @IcahnMountSinai presented this hot abstract at #ASH25, and you can hear all about it in this interview:
🎥
